The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Angina Pectoris Drugs Market Research Report 2025
Synopsis
Angina pectoris is a clinical indication characterized by precordial heaviness or discomfort due to transient myocardial ischemia without infarction, elicited by physical exertion or psychological stress. Angina pectoris is categorized as - stable, unstable, microvascular and Prinzmetal / variant. Angina pectoris is an initial presentation of coronary heart disease (CHD) and exerts a major impact on quality of life (QOL), costs to the society and ability to work.
The global Angina Pectoris Drugs market was valued at US$ 344 million in 2023 and is anticipated to reach US$ 433.4 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris.
This report aims to provide a comprehensive presentation of the global market for Angina Pectoris Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angina Pectoris Drugs.
Report Scope
The Angina Pectoris Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Angina Pectoris Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Angina Pectoris Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Bayer
AstraZeneca
Gilead
Novartis
GlaxoSmithKline
Merck
Mylan
Teva Pharmaceutical
Segment by Type
Beta Blockers
Calcium Antagonists
Anticoagulants
Anti-Platelets
Others
Segment by Application
Hospitals
Clinics
ASCs
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Angina Pectoris Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Angina pectoris is a clinical indication characterized by precordial heaviness or discomfort due to transient myocardial ischemia without infarction, elicited by physical exertion or psychological stress. Angina pectoris is categorized as - stable, unstable, microvascular and Prinzmetal / variant. Angina pectoris is an initial presentation of coronary heart disease (CHD) and exerts a major impact on quality of life (QOL), costs to the society and ability to work.
The global Angina Pectoris Drugs market was valued at US$ 344 million in 2023 and is anticipated to reach US$ 433.4 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris.
This report aims to provide a comprehensive presentation of the global market for Angina Pectoris Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angina Pectoris Drugs.
Report Scope
The Angina Pectoris Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Angina Pectoris Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Angina Pectoris Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Bayer
AstraZeneca
Gilead
Novartis
GlaxoSmithKline
Merck
Mylan
Teva Pharmaceutical
Segment by Type
Beta Blockers
Calcium Antagonists
Anticoagulants
Anti-Platelets
Others
Segment by Application
Hospitals
Clinics
ASCs
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Angina Pectoris Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Angina Pectoris Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Beta Blockers
1.2.3 Calcium Antagonists
1.2.4 Anticoagulants
1.2.5 Anti-Platelets
1.2.6 Others
1.3 Market by Application
1.3.1 Global Angina Pectoris Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 ASCs
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Angina Pectoris Drugs Market Perspective (2019-2030)
2.2 Angina Pectoris Drugs Growth Trends by Region
2.2.1 Global Angina Pectoris Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Angina Pectoris Drugs Historic Market Size by Region (2019-2024)
2.2.3 Angina Pectoris Drugs Forecasted Market Size by Region (2025-2030)
2.3 Angina Pectoris Drugs Market Dynamics
2.3.1 Angina Pectoris Drugs Industry Trends
2.3.2 Angina Pectoris Drugs Market Drivers
2.3.3 Angina Pectoris Drugs Market Challenges
2.3.4 Angina Pectoris Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Angina Pectoris Drugs Players by Revenue
3.1.1 Global Top Angina Pectoris Drugs Players by Revenue (2019-2024)
3.1.2 Global Angina Pectoris Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Angina Pectoris Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Angina Pectoris Drugs Revenue
3.4 Global Angina Pectoris Drugs Market Concentration Ratio
3.4.1 Global Angina Pectoris Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Angina Pectoris Drugs Revenue in 2023
3.5 Angina Pectoris Drugs Key Players Head office and Area Served
3.6 Key Players Angina Pectoris Drugs Product Solution and Service
3.7 Date of Enter into Angina Pectoris Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Angina Pectoris Drugs Breakdown Data by Type
4.1 Global Angina Pectoris Drugs Historic Market Size by Type (2019-2024)
4.2 Global Angina Pectoris Drugs Forecasted Market Size by Type (2025-2030)
5 Angina Pectoris Drugs Breakdown Data by Application
5.1 Global Angina Pectoris Drugs Historic Market Size by Application (2019-2024)
5.2 Global Angina Pectoris Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Angina Pectoris Drugs Market Size (2019-2030)
6.2 North America Angina Pectoris Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Angina Pectoris Drugs Market Size by Country (2019-2024)
6.4 North America Angina Pectoris Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Angina Pectoris Drugs Market Size (2019-2030)
7.2 Europe Angina Pectoris Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Angina Pectoris Drugs Market Size by Country (2019-2024)
7.4 Europe Angina Pectoris Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Angina Pectoris Drugs Market Size (2019-2030)
8.2 Asia-Pacific Angina Pectoris Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Angina Pectoris Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Angina Pectoris Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Angina Pectoris Drugs Market Size (2019-2030)
9.2 Latin America Angina Pectoris Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Angina Pectoris Drugs Market Size by Country (2019-2024)
9.4 Latin America Angina Pectoris Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Angina Pectoris Drugs Market Size (2019-2030)
10.2 Middle East & Africa Angina Pectoris Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Angina Pectoris Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Angina Pectoris Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Angina Pectoris Drugs Introduction
11.1.4 Pfizer Revenue in Angina Pectoris Drugs Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Angina Pectoris Drugs Introduction
11.2.4 Bayer Revenue in Angina Pectoris Drugs Business (2019-2024)
11.2.5 Bayer Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Angina Pectoris Drugs Introduction
11.3.4 AstraZeneca Revenue in Angina Pectoris Drugs Business (2019-2024)
11.3.5 AstraZeneca Recent Development
11.4 Gilead
11.4.1 Gilead Company Detail
11.4.2 Gilead Business Overview
11.4.3 Gilead Angina Pectoris Drugs Introduction
11.4.4 Gilead Revenue in Angina Pectoris Drugs Business (2019-2024)
11.4.5 Gilead Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Angina Pectoris Drugs Introduction
11.5.4 Novartis Revenue in Angina Pectoris Drugs Business (2019-2024)
11.5.5 Novartis Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Detail
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Angina Pectoris Drugs Introduction
11.6.4 GlaxoSmithKline Revenue in Angina Pectoris Drugs Business (2019-2024)
11.6.5 GlaxoSmithKline Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Angina Pectoris Drugs Introduction
11.7.4 Merck Revenue in Angina Pectoris Drugs Business (2019-2024)
11.7.5 Merck Recent Development
11.8 Mylan
11.8.1 Mylan Company Detail
11.8.2 Mylan Business Overview
11.8.3 Mylan Angina Pectoris Drugs Introduction
11.8.4 Mylan Revenue in Angina Pectoris Drugs Business (2019-2024)
11.8.5 Mylan Recent Development
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Company Detail
11.9.2 Teva Pharmaceutical Business Overview
11.9.3 Teva Pharmaceutical Angina Pectoris Drugs Introduction
11.9.4 Teva Pharmaceutical Revenue in Angina Pectoris Drugs Business (2019-2024)
11.9.5 Teva Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
